270 related articles for article (PubMed ID: 18289733)
21. NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer's models.
Bahn G; Park JS; Yun UJ; Lee YJ; Choi Y; Park JS; Baek SH; Choi BY; Cho YS; Kim HK; Han J; Sul JH; Baik SH; Lim J; Wakabayashi N; Bae SH; Han JW; Arumugam TV; Mattson MP; Jo DG
Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12516-12523. PubMed ID: 31164420
[TBL] [Abstract][Full Text] [Related]
22. Phospho-eIF2α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice.
Devi L; Ohno M
PLoS One; 2010 Sep; 5(9):e12974. PubMed ID: 20886088
[TBL] [Abstract][Full Text] [Related]
23. Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease.
Wang P; Zheng X; Guo Q; Yang P; Pang X; Qian K; Lu W; Zhang Q; Jiang X
J Control Release; 2018 Jun; 279():220-233. PubMed ID: 29679667
[TBL] [Abstract][Full Text] [Related]
24. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
[TBL] [Abstract][Full Text] [Related]
25. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
Vassar R
Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
[TBL] [Abstract][Full Text] [Related]
26. Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor
Andrew RJ; De Rossi P; Nguyen P; Kowalski HR; Recupero AJ; Guerbette T; Krause SV; Rice RC; Laury-Kleintop L; Wagner SL; Thinakaran G
J Biol Chem; 2019 Mar; 294(12):4477-4487. PubMed ID: 30692199
[TBL] [Abstract][Full Text] [Related]
27. MiR-340 Reduces the Accumulation of Amyloid-β Through Targeting BACE1 (β-site Amyloid Precursor Protein Cleaving Enzyme 1) in Alzheimer's Disease.
Tan X; Luo Y; Pi D; Xia L; Li Z; Tu Q
Curr Neurovasc Res; 2020; 17(1):86-92. PubMed ID: 31957613
[TBL] [Abstract][Full Text] [Related]
28. Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.
Sadleir KR; Eimer WA; Cole SL; Vassar R
Mol Neurodegener; 2015 Jan; 10():1. PubMed ID: 25567526
[TBL] [Abstract][Full Text] [Related]
29. Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling.
Cho HJ; Jin SM; Youn HD; Huh K; Mook-Jung I
Aging Cell; 2008 Mar; 7(2):137-47. PubMed ID: 18081741
[TBL] [Abstract][Full Text] [Related]
30. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
Andrew RJ; Fernandez CG; Stanley M; Jiang H; Nguyen P; Rice RC; Buggia-Prévot V; De Rossi P; Vetrivel KS; Lamb R; Argemi A; Allaert ES; Rathbun EM; Krause SV; Wagner SL; Parent AT; Holtzman DM; Thinakaran G
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9665-E9674. PubMed ID: 29078331
[TBL] [Abstract][Full Text] [Related]
31. The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis.
Zhao J; O'Connor T; Vassar R
J Neuroinflammation; 2011 Nov; 8():150. PubMed ID: 22047170
[TBL] [Abstract][Full Text] [Related]
32. Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting β/γ-Secretases Activity and Enhancing α-Secretases.
Cai Z; Wang C; He W; Chen Y
Curr Alzheimer Res; 2018; 15(11):1045-1052. PubMed ID: 29962345
[TBL] [Abstract][Full Text] [Related]
33. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.
Chen CH; Zhou W; Liu S; Deng Y; Cai F; Tone M; Tone Y; Tong Y; Song W
Int J Neuropsychopharmacol; 2012 Feb; 15(1):77-90. PubMed ID: 21329555
[TBL] [Abstract][Full Text] [Related]
34. Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence.
Kimura A; Hata S; Suzuki T
J Biol Chem; 2016 Nov; 291(46):24041-24053. PubMed ID: 27687728
[TBL] [Abstract][Full Text] [Related]
35. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
[TBL] [Abstract][Full Text] [Related]
36. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
37. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
[TBL] [Abstract][Full Text] [Related]
38. BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease.
Zhou W; Cai F; Li Y; Yang GS; O'Connor KD; Holt RA; Song W
J Mol Neurosci; 2010 Sep; 42(1):127-33. PubMed ID: 20455082
[TBL] [Abstract][Full Text] [Related]
39. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
40. Gadd153 and NF-κB crosstalk regulates 27-hydroxycholesterol-induced increase in BACE1 and β-amyloid production in human neuroblastoma SH-SY5Y cells.
Marwarha G; Raza S; Prasanthi JR; Ghribi O
PLoS One; 2013; 8(8):e70773. PubMed ID: 23951005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
